You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 119 No. 6, JUNE 1967 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

Supplemental Sulfone (Dapsone) Therapy

Use in Treatment of Chloroquine-Resistant Falciparum Malaria

Lt Col Thomas W. Sheehy, MC; Maj Richard C. Reba, MC; Capt Thomas A. Neff, MC; Capt J. Richard Gaintner, MC; Col William D. Tigertt, MC

Arch Intern Med. 1967;119(6):561-566.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Shortly SHORTLY after the antimalarial activity of the parent sulfone dapsone was discovered, the drug was discarded as too toxic for human use.1-4 This occurred at the time when it was assumed that the amount of sulfone necessary for treatment was similar to that used with the sulfa drugs, ie, 1 to 2 gm daily. As a result, total doses of 36 and 16 gm of dapsone were administered over periods as short as nine days in the first human trials of dapsone as an antimalarial agent.5,6 In both clinical trials, dapsone was effective against Plasmodium falciparum, but later reports of its toxicity1-4 and the successful introduction of the 4-aminoquinoline drugs led to abandonment of dapsone as an antimalarial drug.

In 1949, dapsone was introduced for the treatment of leprosy,7 and soon after small daily doses of dapsone were found to be therapeutically effective and relatively non-toxic (ie, 100 mg or . . . [Full Text PDF of this Article]


Author Affiliations

USA; USA; USA; USA; USA, Republic of Vietnam

From the Walter Reed General Hospital, Walter Reed Army Medical Center (Dr. Sheehy), and the Walter Reed Institute of Research, Washington, DC, (Dr. Tigertt); the Johns Hopkins Medical Institutions (Dr. Reba), and the Department of Hematology, Johns Hopkins Hospital, Baltimore (Dr. Gaintner); and the Department of Hospital Clinics, Fitzsimmons General Hospital, Denver (Dr. Neff). Dr. Sheehy formerly medical consultant, US Army; Drs. Reba, Neff, and Gaintner are formerly of the 85th Evacuation Hospital, Republic of Vietnam.


Footnotes

Received for publication Nov 2, 1966; accepted, Feb 1, 1967.

Reprint requests to Walter Reed Army Medical Center, Washington, DC 20012 (Dr. Sheehy).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1967 American Medical Association. All Rights Reserved.